{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:39:24Z","timestamp":1792449564509,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bmcl.2026.130608","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:19:28Z","timestamp":1772583568000},"page":"130608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design, synthesis, and Lead optimization of novel Quinazoline-based FLT3 inhibitors with potent anti-acute myelogenous leukemia activity"],"prefix":"10.1016","volume":"136","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaibo","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengzheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bmcl.2026.130608_bb0005","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130608_bb0010","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol Rev"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130608_bb0015","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/leu.2014.55","article-title":"Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients","volume":"28","author":"Kihara","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130608_bb0020","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 inhibitors in acute myeloid leukemia: current status and future directions","volume":"16","author":"Larrosa-Garcia","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"58","key":"10.1016\/j.bmcl.2026.130608_bb0025","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.18632\/oncotarget.27222","article-title":"Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells","volume":"10","author":"Kawase","year":"2019","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130608_bb0030","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1021\/acs.jmedchem.0c02247","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130608_bb0035","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"issue":"20","key":"10.1016\/j.bmcl.2026.130608_bb0040","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.3390\/jcm12206429","article-title":"A review of FLT3 kinase inhibitors in AML","volume":"12","author":"Negotei","year":"2023","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.bmcl.2026.130608_bb0045","doi-asserted-by":"crossref","first-page":"11894","DOI":"10.1021\/acs.jmedchem.5c00698","article-title":"Discovery of a potent FLT3 inhibitor (E)-4-(3-(3-Fluoro-4-(morpholinomethyl)styryl)-1H-indazol-6-yl)pyridin-2-amine for the treatment of acute myeloid leukemia with multiple FLT3 mutations","volume":"68","author":"Liu","year":"2025","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130608_bb0050","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1021\/acs.jmedchem.1c02079","article-title":"Identification of the Benzoimidazole compound as a selective FLT3 inhibitor by cell-based high-throughput screening of a diversity library","volume":"65","author":"Tian","year":"2022","journal-title":"J Med Chem"},{"issue":"19","key":"10.1016\/j.bmcl.2026.130608_bb0055","doi-asserted-by":"crossref","first-page":"14664","DOI":"10.1021\/acs.jmedchem.1c01196","article-title":"Discovery of a potent FLT3 inhibitor (LT-850-166) with the capacity of overcoming a variety of FLT3 mutations","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"issue":"24","key":"10.1016\/j.bmcl.2026.130608_bb0060","doi-asserted-by":"crossref","first-page":"21752","DOI":"10.1021\/acs.jmedchem.4c00529","article-title":"Discovery of SILA-123 as a highly potent FLT3 inhibitor for the treatment of acute myeloid leukemia with various FLT3 mutations","volume":"67","author":"Wei","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130608_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.130082","article-title":"Discovery of 3-amide-pyrimidine-based derivatives as potential fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia","volume":"117","author":"Liu","year":"2025","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130608_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.bmcl.2026.130608_bb0075","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719827310","article-title":"Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia","volume":"10","author":"Short","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"14","key":"10.1016\/j.bmcl.2026.130608_bb0080","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2013-04-493916","article-title":"G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia","volume":"123","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130608_bb0085","doi-asserted-by":"crossref","DOI":"10.4081\/oncol.2012.e8","article-title":"An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Oncol Rev"},{"key":"10.1016\/j.bmcl.2026.130608_bb0090","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.hoc.2017.04.005","article-title":"Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment","volume":"31","author":"Ghiaur","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130608_bb0095","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.clml.2016.06.002","article-title":"FLT3 inhibitors for treating acute myeloid leukemia","volume":"16","author":"Hassanein","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7397","key":"10.1016\/j.bmcl.2026.130608_bb0100","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.bmcl.2026.130608_bb0105","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/jm9007533","article-title":"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N\u2032-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine Kinase-3 (FLT3) inhibitor","volume":"52","author":"Chao","year":"2009","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130608_bb0110","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bmcl.2026.130608_bb0115","article-title":"Expanding the toolbox of target directed bio-orthogonal synthesis: in situ direct macrocyclization by DNA templates","volume":"62","author":"Chaudhuri","year":"2023","journal-title":"Angew Chem Int Ed"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130608_bb0120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/scipharm93010006","article-title":"Targeting c-MYC G-Quadruplexes for Cancer treatment with Small molecules","volume":"93","author":"Thumpati","year":"2025","journal-title":"Sci Pharm"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130608_bb0125","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/acsmedchemlett.3c00537","article-title":"Selective recognition of c-KIT 1 G-Quadruplex by structural tuning of Heteroaromatic scaffolds and side chains","volume":"15","author":"Fatma","year":"2024","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130608_bb0130","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1021\/acs.jmedchem.6c00138","article-title":"Discovery of potent HDAC6-selective inhibitors based on artemisinin: design, synthesis, and antitumor evaluation","volume":"69","author":"Liu","year":"2026","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130608_bb0135","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.biopha.2011.11.012","article-title":"Preclinical pharmacokinetic analysis of felotaxel (SHR110008), a novel derivative of docetaxel, in rats and its protein binding ability in vitro","volume":"66","author":"Ding","year":"2012","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130608_bb0140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","article-title":"Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130608_bb0145","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1021\/acs.jmedchem.1c01792","article-title":"Identification of 2-Aminopyrimidine derivatives as FLT3 kinase inhibitors with high selectivity over c-KIT","volume":"65","author":"Tong","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130608_bb0150","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3389\/fphar.2019.00758","article-title":"Apoptotic pathway as the therapeutic target for anticancer traditional Chinese medicines","volume":"10","author":"An","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130608_bb0155","article-title":"Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemia","volume":"7","author":"Jamshid Sorouri","year":"2024","journal-title":"Cancer Drug Resistance"},{"issue":"12","key":"10.1016\/j.bmcl.2026.130608_bb0160","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.3324\/haematol.2018.208843","article-title":"FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways","volume":"104","author":"Min","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.bmcl.2026.130608_bb0165","doi-asserted-by":"crossref","first-page":"1577313","DOI":"10.3389\/fimmu.2025.1577313","article-title":"FLT3-ITD promotes immune checkpoint CD80 via ROS elevation in acute myeloid leukemia","volume":"16","author":"Yan","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmcl.2026.130608_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117788","article-title":"Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: novel molecular approaches and therapeutic challenges","volume":"182","author":"Rataj","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmcl.2026.130608_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106401","article-title":"Inspired by bis-\u03b2-carboline alkaloids: construction and antitumor evaluation of a novel bis-\u03b2-carboline scaffold as potent antitumor agents","volume":"133","author":"Liu","year":"2023","journal-title":"Bioorg Chem"},{"issue":"12","key":"10.1016\/j.bmcl.2026.130608_bb0180","doi-asserted-by":"crossref","first-page":"8066","DOI":"10.1021\/acs.jmedchem.3c00396","article-title":"Discovery of platinum(IV)-Artesunate multiaction prodrugs as potent antitumor and antimalarial agents","volume":"66","author":"Liu","year":"2023","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bmcl.2026.130608_bb0185","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.1021\/acs.jmedchem.4c00784","article-title":"Discovery of novel p53-MDM2 inhibitor (RG7388)-conjugated platinum(IV) complexes as potent antitumor agents","volume":"67","author":"Liu","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130608_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108312","article-title":"Design, synthesis, and biological evaluation of novel artemisinin-based HDAC inhibitors with antitumor and antimalarial activities","volume":"157","author":"He","year":"2025","journal-title":"Bioorg Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:55:10Z","timestamp":1777600510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26000752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"alternative-id":["S0960894X26000752"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130608","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and Lead optimization of novel Quinazoline-based FLT3 inhibitors with potent anti-acute myelogenous leukemia activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130608","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130608"}}